Company intelligence / Profile preview

Avocel

Sunnyvale, California, United States

Ownership: Private
Development stage: Other

Overview

Avocel was a biotechnology company focused on the development of RNA interference (RNAi) therapeutics for the treatment of neurological and other genetic diseases. Founded by pioneers in the RNAi field, the company developed a proprietary platform for the delivery and stabilization of small interfering RNAs (siRNAs). Its primary research focus was on Huntington's disease, utilizing RNAi to silence the expression of the mutant huntingtin gene. The company was acquired by Alnylam Pharmaceuticals in 2004 to bolster Alnylam's intellectual property portfolio and expertise in RNAi delivery and therapeutic applications.

Therapeutic areas: Neurology
Modalities: Small interfering RNARNA therapy
Industry: Biotech

Beyond the preview

Go deeper on Avocel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avocel.

Explore the full profile